Vanguard Group Inc. Has $61.31 Million Holdings in Ocular Therapeutix, Inc. $OCUL

Vanguard Group Inc. lowered its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 1.4% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,364,515 shares of the biopharmaceutical company's stock after selling 119,398 shares during the quarter. Vanguard Group Inc. owned about 5.25% of Ocular Therapeutix worth $61,312,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Deep Track Capital LP raised its position in shares of Ocular Therapeutix by 0.9% during the 4th quarter. Deep Track Capital LP now owns 12,836,282 shares of the biopharmaceutical company's stock valued at $109,622,000 after acquiring an additional 114,822 shares in the last quarter. Point72 Asset Management L.P. lifted its position in shares of Ocular Therapeutix by 43.9% in the 4th quarter. Point72 Asset Management L.P. now owns 2,935,924 shares of the biopharmaceutical company's stock worth $25,073,000 after buying an additional 895,304 shares during the last quarter. Deltec Asset Management LLC boosted its holdings in shares of Ocular Therapeutix by 3.8% in the 1st quarter. Deltec Asset Management LLC now owns 2,716,373 shares of the biopharmaceutical company's stock valued at $19,911,000 after buying an additional 100,000 shares during the period. Northern Trust Corp grew its position in shares of Ocular Therapeutix by 5.5% during the 4th quarter. Northern Trust Corp now owns 1,314,871 shares of the biopharmaceutical company's stock valued at $11,229,000 after buying an additional 68,174 shares during the last quarter. Finally, Peregrine Capital Management LLC acquired a new stake in Ocular Therapeutix during the first quarter worth about $6,212,000. Institutional investors and hedge funds own 59.21% of the company's stock.

Ocular Therapeutix Stock Up 3.8%

Ocular Therapeutix stock traded up $0.45 during mid-day trading on Tuesday, hitting $12.32. 1,766,368 shares of the company's stock were exchanged, compared to its average volume of 2,010,522. The company has a current ratio of 10.10, a quick ratio of 10.02 and a debt-to-equity ratio of 0.23. The stock has a 50 day moving average of $11.06 and a two-hundred day moving average of $8.75. The stock has a market cap of $2.14 billion, a P/E ratio of -9.63 and a beta of 1.49. Ocular Therapeutix, Inc. has a 1-year low of $5.78 and a 1-year high of $12.91.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.04). Ocular Therapeutix had a negative return on equity of 71.92% and a negative net margin of 382.51%.The firm had revenue of $13.46 million for the quarter, compared to analyst estimates of $13.12 million. During the same period in the prior year, the firm earned ($0.26) EPS. The firm's revenue was down 17.7% on a year-over-year basis. As a group, analysts anticipate that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on OCUL shares. HC Wainwright reaffirmed a "buy" rating and set a $15.00 target price on shares of Ocular Therapeutix in a report on Thursday, May 29th. Needham & Company LLC boosted their price target on shares of Ocular Therapeutix from $14.00 to $15.00 and gave the company a "buy" rating in a report on Tuesday, August 5th. Finally, Scotiabank dropped their price objective on shares of Ocular Therapeutix from $22.00 to $20.00 and set a "sector outperform" rating on the stock in a report on Wednesday, August 6th. Five research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $17.20.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.